Livalo Acute Myocardial Infarction Study

Statins are usually used in AMI patients due to its strong anti-lipidemic effect, pleiotropic effect and tolerable safety profiles. Generally AMI patients are prescribed many drugs concomitantly; there are some risks due to the drug interaction. Especially, statins are reported to have many drug interactions, these might influence to therapeutic prognosis and safety in AMI patients.

This study is conducted to administer the non-CYP3A4 metabolized statin, pitavastatin to AMI patients over 1 year, and the results will be compared with the other results from the KAMIR study which is expected to the large scale of AMI patients using statins be enrolled. Finally, from that comparison, we will investigate the influence of the statins metabolism by CYP3A4 to the therapeutic prognosis like death, major adverse cardiac events(MACE), and major ADR of statins like CK increase, myalgia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myocardial Infarction

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiac and Vascular Center, Hanseo Hospital, Busan, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The patients who have taken pitavastatin since AMI

Exclusion criteria

none

Treatment and study plan

Primary outcomes

Death/MACE for 1 year after the registration

Time frame: 1 year

Secondary outcomes

Achievement of LDL cholesterol target level according to the NCEP ATP III guideline

Time frame: 1 year
Abnormal change of lab value including CK etc

Time frame: 1 year
Adverse event including myalgia

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

JW Pharmaceutical

Industry

Registry information

Official study title

A Prospective Clinical Observation Study to Evaluate the Influence of Long Term Treatment of Pitavastatin on the Therapeutic Prognosis and Safety in Acute Myocardial Infarction

Acronym: LAMIS

Important dates

Study start: 2007
Primary completion: 2010
Study completion: 2011
First posted: Dec 10, 2008
Registry last updated: Mar 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed